

February 26, 2025

RE: Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium

Dear Potential Exhibitor:

On behalf of **The University of Texas MD Anderson Cancer Center**, and **Activity Director, Simona Colla, PhD**, and **Co-Activity Director, Guillermo Garcia-Manero, MD**, we would like to invite you to exhibit at our upcoming **Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium**, scheduled for **May 21 – 22, 2025** at **MD Anderson - Main Building, Hickey Auditorium** in **Houston, Texas**. We offer a variety of exhibitor packages, each designed to provide unique opportunities for participation.

OVERVIEW

Myelodysplastic Syndromes (MDS) stand at the forefront of hematologic oncology, presenting a formidable enigma that demands urgent attention. At the heart of this challenge lies the intricate dance of hematopoietic stem cells, whose dysfunction orchestrates the symphony of MDS. The upcoming MDS symposium promises to be a crucible of innovation, uniting the brightest minds in hematopoiesis and MDS research from across the globe. This convergence of expertise will ignite a transformative wave of collaboration, yielding pivotal insights and propelling the field towards groundbreaking molecular and therapeutic breakthroughs. By harnessing the collective genius of international leaders, this symposium aims to shatter the barriers impeding our understanding of MDS, paving the way for transformative treatments that could rewrite the future for patients battling this complex blood cancer.

NEEDS ASSESSMENT

There is a lack of understanding and knowledge of biology and treatment to use the best available therapy that is effective therapy for MDS to improve the outcomes. Therapy with hypomethylating agents remains the standard of care. However, 50% of the patients do not respond to treatment and 50% of the responders' progress to AML with a poor prognosis.

The field of Myelodysplastic Syndromes (MDS) research urgently requires:

1. A unified platform for global collaboration among leading experts in hematopoiesis and MDS.
2. Accelerated progress in understanding the complex biological mechanisms underlying hematopoietic stem cell dysfunction in MDS.
3. Novel approaches to translate scientific insights into innovative therapeutic strategies for MDS patients.
4. A catalyst for breakthrough discoveries that can overcome current barriers in MDS treatment and improve patient outcomes.
5. Enhanced knowledge exchange and cross-pollination of ideas between diverse specialties within the field of hematologic oncology.
6. A focused effort to develop transformative treatments that can significantly alter the prognosis for individuals battling this complex blood cancer.
7. Increased momentum in molecular research to unravel the intricacies of MDS pathogenesis and progression.

By addressing these critical needs through the proposed MDS symposium, we aim to propel the field forward, fostering groundbreaking advancements that have the potential to revolutionize our approach to MDS diagnosis, treatment, and patient care.

KNOWLEDGE GAP

MDS is a complex stem cell disorder with a heterogeneous genetic landscape. Although recent advances in genomic sequencing have revealed numerous recurrent mutations, the full spectrum of genetic alterations and their interactions in MDS pathogenesis are not yet fully elucidated.

COMPETENCE GAP

There exists a significant translational gap between cutting-edge research findings and their practical implementation in clinical settings for MDS treatment. This gap manifests in several key areas:

1. Personalized Medicine
2. Novel Therapies
3. Risk Stratification
4. Treatment Sequencing
5. Management of Comorbidities
6. Quality of Life Considerations
7. Clinical Trial Access

Addressing these competence gaps is crucial for translating the best available evidence into improved outcomes for MDS patients across diverse healthcare settings.

This activity is designed to allow attendees to learn about new research and updates from experts in their field.

OBJECTIVES

At the conclusion of this educational activity, participants should be able to:

- Analyze the biological mechanisms underlying hematopoietic stem cell maintenance in both physiological and stress conditions as they relate to MDS pathogenesis.
- Discuss current and emerging treatment strategies for MDS based on the latest understanding of hematopoietic stem cell biology.
- Interpret diagnostic findings and assess prognostic factors, including molecular analyses, for improved patient management.

PLATINUM – \$10,000

- Five Complimentary Registrations
- Five complimentary reception tickets – Tuesday, May 20, 2025
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website, and the ability to post 3 – 6 product information (pdfs)
- Designated premium location
- 8 networking breaks that occur in and adjacent to the Exhibit Hall
- Platinum level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

GOLD – \$7,500

- Four Complimentary Registrations
- Four complimentary reception tickets – Tuesday, May 20, 2025
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name, company logo, link to company website
- Designated premium location
- 8 networking breaks that occur in and adjacent to the Exhibit Hall
- Gold level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

SILVER – \$5,000

- Three Complimentary Registrations
- Three complimentary reception tickets – Tuesday, May 20, 2025
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage, with company name and link to company website
- Designated location
- 8 networking breaks that occur in and adjacent to the Exhibit Hall
- Silver level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

BRONZE – \$2,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Tuesday, May 20, 2025
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- 8 networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

NON-PROFIT – \$1,500

- Two Complimentary Registrations
- Two complimentary reception tickets – Tuesday, May 20, 2025
- Acknowledgement on the Supporter/Exhibitor Tab on the conference webpage with company name
- Designated location
- 8 networking breaks that occur in and adjacent to the Exhibit Hall
- Bronze level recognition
- 6 ft. exhibit table (draped) with two chairs
- Wireless internet connection
- Complimentary meals (available with exhibitor badge)

CONFERENCE LOCATION

MD Anderson - Main Building, Hickey Auditorium
1515 Holcombe Boulevard
Houston, Texas 77030

EXHIBIT REGISTRATION

[Please Click Here for More Information or To Register.](#)

Navigate to the **'Exhibitors'** tab and click on the blue **'Exhibit at this Event'** button. From there, you can select your preferred package level and complete your registration.

Please note: Registration and an exhibit agreement are necessary to participate as an exhibitor. The exhibit is not considered confirmed until your company has registered, and we have a fully executed agreement. The agreement and payment should be received prior to the activity.

Please let me know if you have any questions or need any additional information for this request. We appreciate your consideration to participate as an exhibitor at this exceptional educational activity.

I look forward to hearing from you soon.

Best,

Cicely A. Simon

Manager, Continuing Education
Continuing Professional Education
The University of Texas MD Anderson Cancer Center

Form **W-9**
(Rev. March 2024)
Department of the Treasury
Internal Revenue Service

Request for Taxpayer Identification Number and Certification

Go to www.irs.gov/FormW9 for instructions and the latest information.

Give form to the requester. Do not send to the IRS.

Before you begin. For guidance related to the purpose of Form W-9, see *Purpose of Form*, below.

Print or type. See Specific Instructions on page 3.	1 Name of entity/individual. An entry is required. (For a sole proprietor or disregarded entity, enter the owner's name on line 1, and enter the business/disregarded entity's name on line 2.) The University of Texas MD Anderson Cancer Center	
	2 Business name/disregarded entity name, if different from above.	
	3a Check the appropriate box for federal tax classification of the entity/individual whose name is entered on line 1. Check only one of the following seven boxes. <input type="checkbox"/> Individual/sole proprietor <input type="checkbox"/> C corporation <input type="checkbox"/> S corporation <input type="checkbox"/> Partnership <input type="checkbox"/> Trust/estate <input type="checkbox"/> LLC. Enter the tax classification (C = C corporation, S = S corporation, P = Partnership) _____ Note: Check the "LLC" box above and, in the entry space, enter the appropriate code (C, S, or P) for the tax classification of the LLC, unless it is a disregarded entity. A disregarded entity should instead check the appropriate box for the tax classification of its owner. <input checked="" type="checkbox"/> Other (see instructions) Agency within the Government of the State of Texas	
	4 Exemptions (codes apply only to certain entities, not individuals; see instructions on page 3): Exempt payee code (if any) 3 Exemption from Foreign Account Tax Compliance Act (FATCA) reporting code (if any) C <i>(Applies to accounts maintained outside the United States.)</i>	
	3b If on line 3a you checked "Partnership" or "Trust/estate," or checked "LLC" and entered "P" as its tax classification, and you are providing this form to a partnership, trust, or estate in which you have an ownership interest, check this box if you have any foreign partners, owners, or beneficiaries. See instructions <input type="checkbox"/>	
	5 Address (number, street, and apt. or suite no.). See instructions. 1515 Holcombe Boulevard	6 City, state, and ZIP code Houston, TX 77030
	7 List account number(s) here (optional)	
		Requester's name and address (optional)

Part I Taxpayer Identification Number (TIN)

Enter your TIN in the appropriate box. The TIN provided must match the name given on line 1 to avoid backup withholding. For individuals, this is generally your social security number (SSN). However, for a resident alien, sole proprietor, or disregarded entity, see the instructions for Part I, later. For other entities, it is your employer identification number (EIN). If you do not have a number, see *How to get a TIN*, later.

Social security number								
			-			-		
or								
Employer identification number								
7	4	-	6	0	0	1	1	8

Note: If the account is in more than one name, see the instructions for line 1. See also *What Name and Number To Give the Requester* for guidelines on whose number to enter.

Part II Certification

Under penalties of perjury, I certify that:

- The number shown on this form is my correct taxpayer identification number (or I am waiting for a number to be issued to me); and
- I am not subject to backup withholding because (a) I am exempt from backup withholding, or (b) I have not been notified by the Internal Revenue Service (IRS) that I am subject to backup withholding as a result of a failure to report all interest or dividends, or (c) the IRS has notified me that I am no longer subject to backup withholding; and
- I am a U.S. citizen or other U.S. person (defined below); and
- The FATCA code(s) entered on this form (if any) indicating that I am exempt from FATCA reporting is correct.

Certification instructions. You must cross out item 2 above if you have been notified by the IRS that you are currently subject to backup withholding because you have failed to report all interest and dividends on your tax return. For real estate transactions, item 2 does not apply. For mortgage interest paid, acquisition or abandonment of secured property, cancellation of debt, contributions to an individual retirement arrangement (IRA), and, generally, payments other than interest and dividends, you are not required to sign the certification, but you must provide your correct TIN. See the instructions for Part II, later.

Sign Here Signature of U.S. person *Omer F. Sultan*

Date 2/11/2025 | 9:47 AM CST

General Instructions

Section references are to the Internal Revenue Code unless otherwise noted.

Future developments. For the latest information about developments related to Form W-9 and its instructions, such as legislation enacted after they were published, go to www.irs.gov/FormW9.

What's New

Line 3a has been modified to clarify how a disregarded entity completes this line. An LLC that is a disregarded entity should check the appropriate box for the tax classification of its owner. Otherwise, it should check the "LLC" box and enter its appropriate tax classification.

New line 3b has been added to this form. A flow-through entity is required to complete this line to indicate that it has direct or indirect foreign partners, owners, or beneficiaries when it provides the Form W-9 to another flow-through entity in which it has an ownership interest. This change is intended to provide a flow-through entity with information regarding the status of its indirect foreign partners, owners, or beneficiaries, so that it can satisfy any applicable reporting requirements. For example, a partnership that has any indirect foreign partners may be required to complete Schedules K-2 and K-3. See the Partnership Instructions for Schedules K-2 and K-3 (Form 1065).

Purpose of Form

An individual or entity (Form W-9 requester) who is required to file an information return with the IRS is giving you this form because they